Although the clinical failures of muscular dystrophy-targeting drugs have branded MSTN inhibitors as a fruitless endeavor, recent advancements in inhibitor application and design offer promising prospects for developing viable MSTN therapeutics. The gene discussed is MSTN; the disease is muscular dystrophy.